Article
New and improved AAVenues: current status of hemophilia B gene therapy
2 Nov 2015
Abstract excerpt
INTRODUCTION: Hemophilia B is a sex linked, monogenic, coagulation disorder caused by a deficiency in functional factor IX protein. Gene therapy for this disorder via systemic administration of an adeno-associated virus (AAV) encoding an optimized factor IX construct has shown considerable success, ameliorating the bleeding phenotype in a number of patients. However challenges to sustained curative gene transfer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
